FDA Urged To Revise Manufacturing Reg To Increase Flexibility For OTCs
This article was originally published in The Tan Sheet
Executive Summary
Drug firms have more flexibility changing production protocols for over-the-counter drugs than pharmaceuticals, but the industry would benefit if FDA regulations allowed supplements for OTC products' chemistry, manufacturing and controls to be done without prior approval, an industry representative says
You may also be interested in...
FDA reopens comment period
FDA will reopen until May 18 the comment period on issues relating to its regulations for chemistry, manufacturing and controls supplements and other changes to approved marketing applications for human drugs, according to a Federal Register notice slated for publication April 16. The agency conducted a public meeting in February to consider comments on issues it should consider in revising those regulations, as required by the FDA Modernization Act of 1997 (1"The Tan Sheet" Feb. 26, 2007, p. 12)...
Health, nutrient content claims final rule interim authority granted in FDA reform bill.
FDA HEALTH, NUTRIENT CONTENT CLAIMS FINAL RULE INTERIM AUTHORITY would be permitted within parameters outlined in the conference report on S 830, the FDA Modernization Act, passed by the House and Senate Nov. 9. Under the bill, FDA may make proposed food claims regulations effective upon publication, pending public comment and publication of a final regulation, when HHS "determines that it is necessary...to improve consumer access to important dietary information and to ban or modify a claim in a prompt fashion," according to an "explanatory statement" accompanying the report.
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.